Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy

Urologia Internationalis

Volumn 87, Issue 4, 2011, Pages 445-449

  Dong, Zhi Long ^a   Lu, Ze Ping ^a   Wang, Han Zhang ^b   Zhang, Li Yuan ^a   Wang, Zhi Ping ^a   Zhang, Yu Fang ^a   Ma, Bao Liang ^a  

^a LANZHOU UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Survivin; Tumor markers; Urinary diversion; Urine nuclear matrix protein 22

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; SURVIVIN;

AGED; ARTICLE; BLADDER CANCER; BRICKER BLADDER; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; INDIANA BLADDER; MAINZ BLADDER; MAJOR CLINICAL STUDY; MALE; ORTHOTOPIC BLADDER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; URINARY DIVERSION; URINE INCONTINENCE;

AGED; CASE-CONTROL STUDIES; CHINA; CYSTECTOMY; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URINARY BLADDER NEOPLASMS; URINARY DIVERSION; URINARY INCONTINENCE;

EID: 84355161604     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000330911     Document Type: Article

References (19)

1. Parkin DM: The global burden of urinary bladder cancer. Scand J Urol Nephrol 2008; 218(suppl 9):12-20.
2. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-675. (Pubitemid 32120143)
3. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE: Radical cystectomy for bladder cancer today: A homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-696. (Pubitemid 46621904)
4. Tefilli MV, Gheiler EL, Tiguert R, Grignon DJ, Forman JD, Pontes JE, Wood DP Jr: Urinary diversion-related outcome in patients with pelvic recurrence after radical cystectomy for bladder cancer. Urology 1999; 53: 999-1004. (Pubitemid 29196318)
5. Canales BK, Anderson JK, Premoli J, Slaton JW: Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage Ta bladder cancer. J Urol 2006; 175: 74-77. (Pubitemid 41797089)
6. Gontero P, Banisadr S, Frea B, Brausi M: Metastasis markers in bladder cancer: A review of the literature and clinical considerations. Eur Urol 2004; 46: 296-311. (Pubitemid 39078562)
7. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S, Kuwano M: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002; 62: 4048-4053. (Pubitemid 34791073)
8. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC: The fibroblast growth factor receptor 3 (FGFR3) mutations is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 1265-1268. (Pubitemid 34292538)
9. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-1264. (Pubitemid 24333190)
10. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281-5285. (Pubitemid 27516364)
11. Miller TE, Beausang LA, Winchell LF, Lidgard GP: Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 1992; 52: 422-427.
12. Soloway MS, Briggman V, Carpinito GA, et al: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363-367. (Pubitemid 126445343)
13. Witjes JA, van der Poel HG, van Balken MR, Debruyne FM, Schalken JA: Urinary NMP22 and karyometry in the diagnosis and followup of patients with superficial bladder cancer. Eur Urol 1998; 33: 387-391. (Pubitemid 28230263)
14. Zippe C, Pandrangi L, Agarwal A: NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161: 62-65. (Pubitemid 29422291)
15. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ: Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161: 388-394.
16. van Rhijn BW, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 2005; 47: 736-748. (Pubitemid 40745338)
17. Frazier HA, Robertson JE, Dodge RK, Paulson DF: The value of pathologic factors in predicting cancer specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993; 71: 3993-4001. (Pubitemid 23172983)
18. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999; 162: 53-57. (Pubitemid 29420879)
19. Carpinito GA, Stadler WM, Briggman JV, et al: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996; 156: 1280-1285. (Pubitemid 26307594)